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practice patterns. CONCLUSIONS: The interviews allowed to extrapolate European
findings to the Asia-Pacific region and therefore improved the validity of the cost-
effectiveness models developed for these countries. In our opinion, this method-
ology represents an acceptable alternative whenmore time-consuming and costly
chart reviews cannot be repeated in multiple countries. The significant economic
burden of OAG was confirmed.
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OBJECTIVES: Topical prostaglandin analogues are safe and effective to treat ocular
hypertension (OHT) and open-angle glaucoma (OAG). The preservatives used in
prostaglandin, however, drops increase the short- to long-term risk of developing
ocular surface disease (OSD). We aimed to compare the 10-year costs and clinical
outcomes with Polyquad®-preserved travoprost to costs and outcomes with ben-
zalkonium chloride (BAK)-preserved prostaglandins in 7 Asian countries.
METHODS: A semi-Markov health economic model was developed. Treatment-
naïve OHT/OAG patients were initiated on treatment with Polyquad®-travoprost,
latanoprost or bimatoprost (1st line) with possible timolol adjunct (2nd line, fixed
combination). The literature provided information on the increased risks of treat-
ment change andOSDdevelopment due to exposure to BAK, and disease evolution.
Further treatment lines, including eye laser/surgery, and other medical resource
usewere obtained using data fromaGermanobservational study (COGIS) thatwere
validated and adapted in each country by clinical experts. Local unit costs were
collected and applied to each resource (All-Payer perspective, 2011 costs). Country-
specific discounting was used. RESULTS: Compared to BAK-preserved prostaglan-
dins, Polyquad-travoprost was dominant (15% less OSD; total costs reductions vs.
latanoprost in Singapore14%, India andMalaysia13%, South Korea9% and vs.
bimatoprost from 2% in Thailand to 19% in South Korea), or else cost-effective
(incremental cost-effectiveness ratios 1,000US$ per OSD-free year gained). In
each country, the estimated reductions in glaucoma medical (non-drug) manage-
ment costs (range from18 to22%), and total OSD costs (from25 to27%), were
significant as per second-order sensitivity analysis. As a long-term consequence of
the modeled lower persistence and impaired compliance the presence of OSD was
associated with higher total costs. CONCLUSIONS: This multi-country model esti-
mated that treating Asian OHT/OAG patientswith Polyquad®-preserved travoprost
would generate significantly less OSD compared to BAK-preserved prostaglandins,
together with savings on glaucoma and OSD management costs.
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OBJECTIVES: Prostaglandin analogues are approved as a first-line treatment of
ocular hypertension (OHT) and open-angle glaucoma (OAG). Existingmolecules are
often preserved with benzalkonium chloride (BAK), which is known to create dry
eye. We aimed to assess the long-term impact of the type of preservative used in
prostaglandins on OHT/OAG treatment outcomes and costs in Hong Kong.
METHODS: A semi-Markov model was developed to evaluate the 10-year dry eye
rate andmanagement costs of OHT/OAG patients initiating a treatmentwith either
Polyquad®-preserved travoprost or latanoprost and bimatoprost (both BAK-pre-
served). The probability of experiencing dry eye was obtained from literature.
Switch rates to surgical or medical treatment were taken from UK/US health care
databases. Local unit costs (‘All-payer’ perspective, 2011 private and public tariffs)
were applied to the medical resources collected in a German retrospective chart
review, re-assessed and adapted to the local practice by 3 clinical experts. Discount
rate was 3% for costs and outcomes. A second-order sensitivity analysis provided
95% confidence intervals. RESULTS: The 10-year clinical and economic outcomes
were significantly improved with travoprost compared to BAK-preserved latano-
prost: dry eye rate decreased from 53% [45;59%] to 35% [31;38%], the proportion of
patients reaching a 3rd line treatment from 85% [80;88%] to 57% [44;68%], the sur-
gery rate dropped from 3.0% [2.4;3.5%] to 1.3%.[0.6;1.8%] while the total costs were
significantly reduced by 25% (private setting) and 29% (public setting) vs. latano-
prost, mostly due to a 33% reduction in glaucoma non-drugmanagement cost. The
benefits vs. bimatoprost were similar. The impact of the presence of OSD on costs
was sizeable, and the treatment switch rate was an important cost driver.
CONCLUSIONS: This model suggests a favorable impact of using travoprost rather
than BAK-preserved prostaglandins on 10-year clinical outcomes, which generates
savings on total costs (20-30%) due to reduced medical management costs.
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OBJECTIVES: Safety and efficacy of tafluprost for open-angle glaucoma or ocular
hypertension (OH) have been proven in clinical trials. While tafluprost and latano-
prost have similar efficacy, the absence of the preservative benzalkonium chloride
(BAK) in tafluprost may make it a preferred alternative for patients who are intol-
erant to BAK (i.e., reduces adverse ocular symptoms such as irritation and dry eye).
Reduced ocular symptoms offer clinical/QoL benefits and cost savings associated
with less rescue medication use (artificial tears). Further, the single-dose unit for-
mulation of tafluprost is predicted to lessenmedicationwastage and thus generate
cost savings versus latanoprost (dispensed in multi-dose bottles). These cost-sav-
ings are quantified and cost-effectiveness ratios are calculated in the current study.
METHODS: Resource usage and associated costs are quantified to determine cost
savings offered by tafluprost over latanoprost. Disutility fromadverse ocular symp-
toms caused by preservatives is also determined via a systematic review of litera-
ture to transform tafluprost’s superior tolerability to QALYs. The perspective of this
analysis is the Australian health care system. RESULTS: Preservative-free taflu-
prost was shown to be a highly cost-effective, most likely dominant, strategy over
preserved latanoprost. The likely cost savings due to reducedmedication wastage,
informed by the pattern of latanoprost utilisation observed in the Australian drug
reimbursement system (PBS), in itself wouldmake tafluprost a cost-saving strategy
versus latanoprost. The available evidence suggested that 47.6% of patients on
preserved latanoprost experience some adverse ocular symptoms, while this is
expected to be 29.0%with preservative-free tafluprost. Average cost savings attrib-
utable to reduced artificial tear use was estimated to be $23.64 per patient per year.
This superior tolerability is also estimated to produce an incremental QALY of
0.0107 for preservative-free tafluprost each year when compared with preserved
latanoprost. CONCLUSIONS: Preservative-free tafluprost is a highly cost-effective,
most likely dominant, strategy over preserved latanoprost.
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OBJECTIVES: To investigate the cost-effectiveness of a hypothetical community
screening and subsequent treatment programme for glaucoma in comparisonwith
current practice (i.e. with no screening programme but with some opportunistic
case finding), in both urban and rural areas of India.METHODS: A decision analyt-
ical model was built to model events, costs and treatment pathways with and
without a hypothetical screening programme for glaucoma for a population aged
between 40-69 years age in urban and rural areas. The treatment pathway included
both primary open-angle glaucoma and angle closure disease. Screening and treat-
ment costs were obtained from an administrator of a tertiary eye hospital in India.
The probabilities for each pathway (i.e. for urban and rural areas) were derived
from published literature and expert opinion (Glaucoma specialist currently prac-
ticing in India). The glaucoma prevalence rates for urban and rural areas were
adapted from the Chennai Glaucoma Study findings. Separate decision analytical
models for urban and rural areaswere built for calculating the cost-effectiveness of
community screening for glaucoma in comparison to current practice (i.e. no
screening programmewith some opportunistic case finding). The outcomes calcu-
lated were the incremental cost of screening (i.e. compared with no screening), the
additional cases treated with screening; and the cost per QALY gained by
screening. RESULTS: The introduction of a community screening programme for
glaucoma is likely to be cost-effective, the estimated ICER values beingx 8312.71 for
urban areas and x 7292.30 for rural areas, when compared with no screening pro-
gramme. The community screening for glaucoma would treat an additional 4443
cases and 2872 cases, and prevent 1790 person-years of blindness, and 1150 per-
son-years of blindness over a 10-year period, in urban and rural areas respectively.
CONCLUSIONS: If adequate resources (trained medical personnel and equipment)
is available the likelihood of community screening for glaucoma to be cost-effec-
tive and have an impact on reducing glaucoma-related blindness burden, remains
high in India.
SENSORY SYSTEMS DISORDERS - Patient-Reported Outcomes & Patient
Preference Studies
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OBJECTIVES: To quantify the health burden associated with vision problems in
Singaporean Malays and Indians, using the EQ-5D health index. METHODS: The
Singapore Malay Eye Study (SiMES) and the Singapore Indian Eye Study (SINDI)
were population-based studies of 3,259 Malays (mean age: 59 years; range: 40 to 80;
male: 48.1%) and 3,397 Indians (mean age: 58 years; range: 43 to 84; male: 50.2%),
respectively. Each participant was given a comprehensive eye assessment and
answered the EQ-5D questions. The impact of presenting bilateral visual impair-
ment and 5 major eye conditions (i.e. age-related macular degeneration (AMD),
glaucoma, cataract, diabetic retinopathy, and refractive error) on the EQ-5D health
index score was estimated using separate linear regression models. According to
USdefinition, lowvision is defined as 0.30LogMAR1.00 and blindness as LogMAR
1.00. RESULTS: After adjusted for age, gender and co-morbidities, Singapore Ma-
lays with low vision in one eye and normal vision in the other eye (difference:
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